Citations

Clear

4847 citation(s) found for "Tu, Eric".

Neuropsychiatric symptoms cluster and fluctuate over time in behavioral variant frontotemporal dementia
Morrow, Christopher B. , Eldaief, Mark C. , Rezaii, Neguine, Wong, Bonnie , McGinnis, Scott, Darby, Ryan, Staffaroni, Adam M. , Pascual, Belén , Masdeu, Joseph C. , Tsapkini, Kyrana , Huey, Edward D. , Fisher, Daniel , Balaji, Akshata, Sah, Eric , Rascovsky, Katya, Ghoshal, Nupur , Domoto‐Reilly, Kimiko , Kornak, John , Onyike, Chiadi U. , Huang, Eric J. , Yokoyama, Jennifer S. , Paulson, Henry L. , Wong, Bonnie , Damme, Philip Van , Barmada, Sami J. , Rezaii, Neguine , Sah, Eric , Paulson, Henry L , Van Damme, Philip , Pascual, Belen , Yokoyama, Jennifer , Domoto-Reilly, Kimiko , Barmada, Sami , Morrow, Christopher , Kamath, Vidyulata , Dickerson, Bradford Clark , Lapid, Maria I. , Rojas, Julio C., Masdeu, Joseph C , Pantelyat, Alexander , Balaji, Akshata, Litvan, Irene

Mayo Clinic

Psychiatry and Clinical Neurosciences | March 13, 2025 | Volume: 79 | Issue: 6 | Pages: 327-335

10.1111/pcn.13810 | PMID 40079430 Get It

Aim Cognitive and behavioral phenomena define behavioral variant frontotemporal dementia (bvFTD), but neuropsychiatric symptoms (NPS) outside the core criteria are common throughout the illness. Identifying how NPS cluster in bvFTD may guide development of future therapies. Methods Participants ( n = 354) with sporadic and genetic bvFTD were enrolled in the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Consortium. Dementia stage was defined as early (CDR® plus NACC FTLD ≤1) or advanced (CDR® plus NACC FTLD ≥1). Baseline and annual follow‐up visit data were analyzed to compare NPS across stages of bvFTD. Psychiatric states were captured using the Neuropsychiatric Inventory‐Questionnaire and Clinician Judgment of Symptoms. Polychoric cluster analysis was used to describe NPS clusters. Results NPS were highly prevalent (≥90%) in early and late bvFTD. Four NPS clusters were identified based on magnitude of factor loadings: affective, disinhibited, compulsive, and psychosis. Neuropsychiatric symptoms fluctuated across visits. In the affective cluster, depression showed the least visit‐to‐visit stability. In the disinhibited cluster, elation showed the least stability. Symptoms in the psychosis and compulsive clusters (hallucinations, delusions, obsessions/compulsions, and hyperorality) were largely stable, persisting from visit‐to‐visit in more than 50% of cases. Symptoms in the affective and disinhibited cluster were associated with the highest caregiver burden, while symptoms in the obsessive cluster were associated with the most functional impairment. Conclusion NPS in bvFTD are frequent and cluster into four discrete groups. The fluctuating nature of some NPS in bvFTD suggests that they may not be reliable markers of disease progression or stage.
A mixed-methods study assessing the performance of a clinical decision support tool for Clostridioides difficile testing for patients receiving laxatives
Peaper, David R. , Rathod, Shardul N , Sussman, L. Scott , Azar, Marwan M. , Murdzek, Christina, Roberts, Scott C. , Tichy, Eric M. , Topal, Jeffrey , Kashyap, Nitu , McManus, Dayna , Topal, Jeffrey E , Martinello, Richard A , Azar, Marwan M

Mayo Clinic

Infection Control & Hospital Epidemiology | March 13, 2025 | Volume: 46 | Issue: 5 | Pages: 497-503

10.1017/ice.2025.30 | PMID 40079209 Get It

Abstract Objective: To better understand clinicians’ rationale for ordering testing for C. difficile infection (CDI) for patients receiving laxatives and the impact of the implementation of a clinical decision support (CDS) intervention. Design: A mixed-methods, case series was performed from March 2, 2017 to December 31, 2018. Setting: Yale New Haven Hospital, a 1,541 bed tertiary academic medical center. Participants: Hospitalized patients ≥ 18 years old, and clinicians who were alerted by the CDS. Intervention: CDS was triggered in real-time when a clinician sought to order testing for CDI for a patient who received one or more doses of laxatives within the preceding 24 hours. Results: A total of 3,376 CDS alerts were triggered during the 21-month study period from 2,567 unique clinician interactions. Clinicians bypassed the CDS alert 74.5% of the time, more frequent among residents (48.3% bypass vs. 39.9% accept) and advanced practice providers (APPs) (34.9% bypass vs. 30.6% accept) than attendings (11.3% bypass vs. 22.5% accept). Ordering clinicians noted increased stool frequency/output (48%), current antibiotic exposure (34%), and instructions by an attending physician to test (28%) were among the most common reasons for overriding the alert and proceeding with testing for CDI. Conclusions: Testing for CDI despite patient laxative use was associated with an increased clinician concern for CDI, patient risk for CDI, and attending physician instruction for testing. Attendings frequently accepted CDS guidance while residents and APPs often reinstated CDI test orders, suggesting a need for greater empowerment and discretion when ordering tests.
Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin–Deficient Individuals with Tobacco Smoking History from the SPIROMICS Cohort
Barjaktarević, Igor , Hixson, Roxana, Zhuang, Zian , Buhr, Russell G. , Tejwani, Vickram , Barr, R. Graham, Bateman, Lori A. , Bhatt, Surya P. , Bleecker, Eugene R. , Cooper, Christopher B., Fortis, Spyridon , Hansel, Nadia N. , Hoffman, Eric A. , Martinez, Fernando J., Meyers, Deborah A., Paine, Robert, Pirozzi, C.S. , Sandhaus, Robert A. , Tashkin, Donald P., Wells, J. Michael , Woodruff, Prescott G. , Ortega, Victor E. , Drummond, M Bradley , Fortis, Spyridon , Hoffman, Eric A , Wells, J Michael , Barjaktarevic, Igor , Buhr, Russell G , Bhatt, Surya P , Barr, R. Graham, Curtis, Jeffrey L. , Drummond, Michael , Ghosh, Auyon , Han, MeiLan King , Ohar, Jill , Meyers, Deborah A. , Strange, Charlie

Mayo Clinic

Annals of the American Thoracic Society | March 11, 2025 | Volume: 22 | Issue: 7 | Pages: 998-1008

10.1513/annalsats.202411-1209oc | PMID 40068143 Get It

Abstract Rationale Reliable data about the natural history of lung function decline in alpha-1 antitrypsin (AAT)-deficient Pi*MZ heterozygotes is largely missing. Objectives We hypothesized that, in adults with a tobacco smoking history, lung function deteriorates faster in Pi*MZ compared with the Pi*MM genotype. Methods We identified 1,856 Pi*MM and 79 Pi*MZ participants with ⩾20 pack-years tobacco smoking history from the SPIROMICS (Subpopulations and Intermediate Outcomes Measures in COPD Study) cohort by DNA sequencing and followed them over a median of 4.8 years, comparing radiographic and clinical characteristics between the two groups over time using regression models. Results Adjusted for age, sex, race, smoking pack-year history, and smoking status, Pi*MZ participants had a lower baseline percent predicted forced expiratory volume in 1 second (FEV1) (65.4% vs. 75.1%; difference 95% confidence interval [CI], −15.4% to −3.9%), more radiographic emphysema (<−950 Hounsfield units%, 12.9% vs. 7.8%; difference 95% CI, 2.8% to 7.5%), and nonsignificantly lower lung density. In the longitudinal analysis, the FEV1 annual rate of decline was similar in both groups over the course of the study (−34.5 ml/yr vs. −34.6 ml/yr for Pi*MZ and Pi*MM; difference 95% CI, −16.9 to 17.1 ml/yr). There were no significant differences between Pi*MZ and Pi*MM individuals in the annualized change in lung density, emphysema, patient-reported outcomes, exacerbations, or survival. The proportion with faster FEV1 decline (annual loss ⩾40 ml) was similar in Pi*MZ and Pi*MM groups. In both groups, faster FEV1 decline was associated with more air trapping and small airway disease at baseline. In Pi*MZ only, faster decline was associated with higher blood eosinophil counts (310 vs. 220 cells/μl; difference 95% CI, 30 to 140 cells/μl). In the subgroup analysis limited to a small number of currently smoking participants, no significant differences in longitudinal outcomes were found. Conclusions Despite a lower FEV1 and more emphysema at enrollment, the longitudinal analysis did not demonstrate significantly greater lung function decline or lung density loss in Pi*MZ compared with Pi*MM participants with tobacco smoking history. Limited sample size and duration of longitudinal follow-up constrain generalizability of our findings, thus prohibiting the conclusion that longitudinal trajectories did not differ between these groups. However, our results may suggest that earlier life events could be responsible for more extensive lung disease at enrollment in Pi*MZ compared with Pi*MM tobacco-exposed individuals.
The relationship between performance validity test failure, fatigue, and psychological functioning in Long COVID
Minor, Greta , Kessler, Olivia R., Fry, Laura, Huizenga, Brooke , Naini, Savana M. , Shen, Chen , Wiitala, Sophie J., Eskridge, Courtney, Holker, Erin , Logemann, Allison, Waldron, Eric J. , Whiteside, Douglas M. , Basso, Michael R. , Waldron, Eric J , Whiteside, Douglas , Johnson, Sara

Mayo Clinic

The Clinical Neuropsychologist | March 8, 2025 | Volume: 40 | Issue: 1 | Pages: 242-257

10.1080/13854046.2025.2476798 | PMID 40056074 Get It

Clinical Outcomes With Normothermic Pulsatile Organ Perfusion in Heart Transplantation: A Report From the OCS Heart Perfusion Registry
Stehlik, Josef , Farr, Maryjane , Mehra, Mandeep R. , Schroder, Jacob N. , D’Alessandro, David A. , Pal, Jay D. , Villavicencio, Mauricio A. , Gruber, Peter J. , Couper, Gregory S., Shudo, Yasuhiro , Patel, Parag C. , Daneshmand, Mani A. , Klein, Liviu , Shah, Ashish S. , Skipper, Eric, Esmailian, F., Goldstein, Daniel J. , Ohira, Suguru , Kaczorowski, David, Takeda, Koji , Malyala, R., Haft, Jonathan W., Sun, Benjamin , Kilic, Arman , Anyanwu, Anelechi, Williams, Celeste T. , Kai, Masashi , Sulemanjee, Nasir , Funamoto, Masaki , Salerno, Christopher T. , Durham, Lucian A. , Shaffer, Andrew , Zhou, Xiang , Milano, Carmelo A. , Farr, Maryjane A , Goldstein, Daniel , Lozonschi, Lucian , Takeda, Koji , Meyer, Dan M , Sun, Benjamin C , Pretorius, Victor , Pham, Duc T , Kai, Masashi , Sulemanjee, Nasir Z , Funamoto, Masaki , Durham, Lucian A , Shaffer, Andrew , Zafar, Farhan , Pinney, Sean P , Milano, Carmelo A , Mehra, Mandeep R , Lozonschi, Lucian , Pretorius, Victor , Itoh, Akinobu , Ikonomidis, John S.

Mayo Clinic

Circulation | March 7, 2025 | Volume: 151 | Issue: 13 | Pages: 896-909

10.1161/circulationaha.124.071743 | PMID 40052272 Get It

BACKGROUND: A preservation system, the Organ Care System (OCS; TransMedics) uses normothermic pulsatile perfusion during organ transport for heart transplantation. This system has demonstrated favorable outcomes in hearts recovered from extended-criteria donors after brain death (DBD) and donors after circulatory death (DCD). METHODS: The OCS Heart Perfusion Registry collects data on US heart transplantations using the OCS, static cold storage (SCS), or thoracoabdominal normothermic regional perfusion (NRP) and donor hearts recovered from DBD or DCD donors. We analyzed donor and recipient characteristics and posttransplantation outcomes in patients transplanted with OCS donor hearts (either DBD or DCD) compared with SCS hearts, and with OCS hearts from DCD donors compared with those recovered with NRP followed by SCS. Propensity score matching was used in survival analyses to adjust for differences among recipient characteristics. RESULTS: Between 2021 and 2023, 3225 consecutive heart transplantations enrolled from 56 centers were analyzed in the Heart Perfusion Registry. The OCS was used in 854 of 3225 heart transplantations (26.4%), among which 340 (39.8%) were DBD and 514 (60.2%) were DCD donors, whereas 2174 DBD donors were recovered with SCS and another 197 DCD donors with NRP techniques. The OCS-DBD group experienced a greater number of organ offer refusals before final acceptance (13 versus 6; Wilcoxon rank sum, P <0.001) and a longer transport distance (667 miles versus 232 miles; Wilcoxon rank sum, P <0.001) compared with SCS-DBD. Survival at 12 months was similar between the 2 groups (89.9% for OCS-DBD versus 90.6% for SCS-DBD; marginal Cox model, P =0.54). Among the OCS-DCD and SCS-DBD groups, survival at 12 months was also similar (91.0% versus 92.5%, respectively; marginal Cox model, P =0.32). The OCS-DCD and NRP-DCD groups demonstrated similar survival (91.0% versus 91.7%, respectively; log rank, P =0.63), although the transport distance was longer in OCS-DCD compared with DCD with NRP followed by SCS (400 miles versus 223 miles; Wilcoxon rank sum, P <0.001). By 2023, 90% of all OCS donor management and recovery was performed with dedicated organ recovery teams. CONCLUSIONS: We demonstrate that real-world implementation of the OCS for DBD donors (using predominantly a dedicated recovery team) is associated with expanded donor criteria, longer transport distance, and excellent posttransplantation outcomes. In OCS-DCD donors, outcomes parallel those of donors recovered with NRP-DCD and compare favorably with DBD donor organs.
Macrophage peroxisomes guide alveolar regeneration and limit SARS-CoV-2 tissue sequelae
Wei, Xiaoqin , Qian, Wei , Narasimhan, Harish , Chan, T. K., Liu, Xue , Arish, Mohd , Young, Scott , Li, Chaofan , Cheon, In Su , Yu, Qing , Santos, Gislane de Almeida , Yeatts, Eric V., Spear, Olivia J., Yi, Mou, Hahn, Young S. , Kaplan, Mark H. , Sperling, Anne I. , Shim, Yun M. , Vassallo, Robert , Chen, Peter , Roden, Anja C. , Que, Jianwen , Chan, Ting , Young, Samuel , de Almeida Santos, Gislane , Zhao, Xiao-Yu , Yeatts, Eric V , Parimon, Tanyalak , Fang, Yinshan , Hahn, Young S , Bullock, Timothy N J , Somerville, Lindsay A , Kaplan, Mark H , Sperling, Anne I , Shim, Yun Michael , Vassallo, Robert , Chen, Peter , Ewald, Sarah E , Roden, Anja C , Que, Jianwen , Jiang, Dianhua , Sun, Jie , Li, Chaofan , Yi, Megan, Somerville, Lindsay , Sun, Jie

Mayo Clinic

Science | March 6, 2025 | Volume: 387 | Issue: 6738 | Pages: No page available

10.1126/science.adq2509 | PMID 40048515 Get It

Peroxisomes are vital but often overlooked metabolic organelles. We found that excessive interferon signaling remodeled macrophage peroxisomes. This loss of peroxisomes impaired inflammation resolution and lung repair during severe respiratory viral infections. Peroxisomes were found to modulate lipid metabolism and mitochondrial health in a macrophage type-specific manner and enhanced alveolar macrophage-mediated tissue repair and alveolar regeneration after viral infection. Peroxisomes also prevented excessive macrophage inflammasome activation and IL-1β release, limiting accumulation of KRT8 high dysplastic epithelial progenitors following viral injury. Pharmacologically enhancing peroxisome biogenesis mitigated both acute symptoms and post-acute sequelae of COVID-19 (PASC) in animal models. Thus, macrophage peroxisome dysfunction contributes to chronic lung pathology and fibrosis after severe acute respiratory syndrome coronavirus 2 infection.
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Zarif, Talal El , Denu, Ryan , Abdel‐Wahab, Noha , Freeman, Dory , Hayeck, Salim, Anderson, Élizabeth , Goodman, Rachel , Johnson, Douglas B. , Grynberg, Shirly , Shapira, Ronnie, Kwan, Jennifer M. , Long, Georgina V. , Haykal, Tarek , Kojima, Yuki , Yonemor, Kan, Trevino, Alexandra , Hui, Gavin , Drakaki, Alexandra, El‐Am, Edward , Al‐Hader, Ahmad, Babu, P. Narendra , Li, Mingjia , Jones, N. , Herrera, M., Foderaro, Simone , Kim, Chul , Sackstein, Paul , Desai, Aakash , Smith, Caleb J. , Korolewicz, James , Lopetegui‐Lia, Nerea , Funchain, Pauline , Choudhary, Arrush, Asnani, Aarti , Stukalin, Igor , Gallegos, Jesús Antonio Ocejo , Nusrat, Sanober , Malvar, Carmel, McKay, Rana R. , Neilan, Tomas G. , Naqash, Abdul Rafeh , Baena, Javier , El Zarif, Talal , Goodman, Rachel S , Kim, Chul , Desai, Aakash P , Cortellini, Alessio , Pinato, David J , Navani, Vishal , Ocejo Gallegos, Jesus Antonio , Funchain, Pauline , Long, Georgina V , Naqash, Abdul Rafeh , Grynberg, Shirly , Espinar, Javier Baena , Alaiwi, Sarah Abou , Macaron, Walid , Vasbinder, Alexi L. , Woodford, Rachel , Dent, Susan , Kojima, Yuki, Tandon, Ankita, Akhter, Nausheen , Yang, Eric H. , Kozaily, Elie , Farhat, Elias Bou , Mittra, Arjun , Jones, Nicholas, Baena, Javier, Nana, Frank Aboubakar , Parikh, Kaushal , Cortellini, Alessio , Pinato, David J. , Meyers, Daniel E. , Trent, Jonathan C. , Choueiri, Toni K. , Korolewicz, James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 3, 2025 | Volume: 13 | Issue: 3 | Pages: e009364

10.1136/jitc-2024-009364 | PMID 40032601 Get It

Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline. Patients who had received ≥1 dose of ICI were included. Treatment-related adverse events (trAEs) were graded per Common Terminology Criteria for Adverse Event V.5.0. Objective response rates (ORR) were evaluated by Response Evaluation Criteria in Solid Tumors V.1.1 when available. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Results Among 110 pts, median age at ICI initiation was 65 (IQR: 59–75). Median follow-up time since ICI initiation was 36 (95% CI: 26 to 51) months. Melanoma (38%, n=42) and non-small cell lung cancer (24%, n=26) were the most common. 68 (62%) patients received ICIs as first-line, and 29 (26%) patients were treated with combination anti-programmed death-1 and anti-cytotoxic T-lymphocyte antigen 4. The most common location of cardiac metastasis was in the atria (37%, n=41) and ventricles (35%, n=39). 15 patients (13.6%) had bilateral cardiac/pericardial metastasis, 44 (40%) had left-sided, and 43 (39.8%) had right-sided. At ICI initiation, 21% (n=23) had a cardiac thrombus. Cardiology referrals and cardiac MRIs at the time of cancer diagnosis were completed on 58 (53%) and 52 (47%) patients, respectively. Cardiac events occurred in 40 (36%) patients, including arrhythmias (n=14, 13%), arterial/venous emboli (n=4, 3.6%), and cardiac tamponade (n=3, 2.7%). 53 (47%) patients developed trAEs; most common were colitis/diarrhea (n=16, 15%), dermatitis (n=13, 12%), and hepatitis (n=9, 8.2%). ICI-related major cardiac trAEs occurred in 2 (1.8%) patients. 22 patients (20%) developed grade ≥3 trAE. Patients with multiple cardiac metastases had significantly lower responses to ICI-based regimens compared with patients with single cardiac metastasis (11% vs 63%, p=0.02). For melanoma, ORR, median PFS, and median OS were 38%, 9.0 months, and 28.9 months, respectively. 83% of patients with melanoma had concordant responses in overall disease burden and cardiac disease. 91 patients discontinued ICIs, and the main reason was progression or death in 55 (49%) patients. Conclusions Among patients with pre-existing cardiac metastasis, ICIs demonstrated meaningful clinical efficacy with no increase in safety signals. Most patients had concordant responses in the overall disease burden and cardiac mass. Multidisciplinary teams are crucial for the appropriate management of patients with cardiac metastasis.
Clinical progression of clonal hematopoiesis is determined by a combination of mutation timing, fitness, and clonal structure
Latorre‐Crespo, Eric , Robertson, Neil , Kosebent, E. Gozde, Uddin, Md Mesbah , Honigberg, Michael C. , Bick, Alex, Reiner, Alexander P., Fiorillo, Edoardo , Chandra, Tamir , Kirschner, Kristina , Chandra, Tamir , Robertson, Neil A , Uddin, Md M , Honigberg, Michael C , Harris, Sarah , Schumacher, Linus , Chandra, Tamir , Kirschner, Kristina , Latorre, Eric , MacGillivray, Louise , Murphy, Lee , Whitsel, Eric A , Orrù, Valeria , Marongiu, Michele , Cucca, Francesco , Deary, Ian J. , Cox, Simon R. , Marioni, Riccardo E.

Mayo Clinic

No container title available | March 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.02.28.640879 | PMID 40093158 Get It

Abstract Clonal hematopoiesis (CH) is characterized by expanding blood cell clones carrying somatic mutations in healthy aged individuals and is associated with various age-related diseases and all-cause mortality. While CH mutations affect diverse genes associated with myeloid malignancies, their mechanisms of expansion and disease associations remain poorly understood. We investigate the relationship between clonal fitness and clinical outcomes by integrating data from three longitudinal aging cohorts (n=713, observations=2,341). We demonstrate pathway-specific fitness advantage and clonal composition influence clonal dynamics. Further, the timing of mutation acquisition is necessary to determine the extent of clonal expansion reached during the host individual’s lifetime. We introduce MACS120, a metric combining mutation context, timing, and variant fitness to predict future clonal growth, outperforming traditional variant allele frequency measurements in predicting clinical outcomes. Our unified analytical framework enables standardized clonal dynamics inference across cohorts, advancing our ability to predict and potentially intervene in CH-related pathologies.
LGBTQ+ Mental Health
Rafla-Yuan, Eric , Fonseca, Fiona, Dixon, Lisa B. , Fonseca, Fiona Fí

Mayo Clinic

Psychiatric Services | March 1, 2025 | Volume: 76 | Issue: 3 | Pages: 312-313

10.1176/appi.ps.25076005 | PMID 41920685 Get It

The AANS/CNS Section on Pediatric Neurological Surgery domestic traveling fellowship: history and survey results of past recipients
Stadnik, Agnieszka , Blatt, Jason E. , Ahn, Edward S. , Thompson, Eric M.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | February 28, 2025 | Volume: 35 | Issue: 5 | Pages: 505-511

10.3171/2024.11.peds24455 | PMID 40020228 Get It

OBJECTIVE The American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) Section on Pediatric Neurological Surgery domestic traveling fellowship was created to cover the travel and living expenses for a North American neurosurgery resident for 1 month at another institution to gain experience in pediatric neurosurgery. The objective of this work was to guide future direction by surveying past recipients about the fellowship and its impact on their training and career. METHODS Historical data have been maintained by the AANS/CNS Executive Committee and past and current chairs of the Traveling Fellowship Subcommittee. A 10-question REDCap survey was emailed to all previous fellowship recipients. RESULTS There have been 58 recipients of the traveling fellowship since 1998. The most common host program was Boston Children’s Hospital (n = 21), followed by The Hospital for Sick Children (n = 12). Excluding recent recipients after 2017 who may still be working toward certification, 20 of 38 (53%) recipients have been certified by the American Board of Pediatric Neurological Surgery (ABPNS). Twenty-four of 49 (49%) recipients completed the survey. Twenty (83.3%) respondents were either ABPNS certified or planning to seek certification, 17 (70.8%) respondents’ practices consisted of > 50% patients aged ≤ 21 years, and 18 (75%) spent 4–8 weeks at the host program, which was longer than the 1 month funded by the stipend. Twenty-two (91.7%) respondents would recommend the traveling fellowship to a resident interested in pediatric neurosurgery, and 18 (75%) believed the traveling fellowship helped them decide to pursue a career in pediatric neurosurgery, while 17 (70.8%) found that the professional connections they made were the most useful aspect of the fellowship. Fifteen (62.5%) respondents believed that the stipend of $2500 was inadequate to cover the cost of traveling and housing. CONCLUSIONS The majority of respondents are currently practicing pediatric neurosurgeons, would recommend the traveling fellowship to residents interested in neurosurgery, and believed that the experience helped them decide to pursue a career in pediatric neurosurgery. Opportunities for improvement include increasing the stipend to more appropriately fund rotations that have mostly been longer than 1 month.